ALB and esophageal squamous cell carcinoma: Previous studies[9,10] have confirmed that albumin-bound paclitaxel has shown good clinical efficacy in the treatment of advanced ESCC, but the role of this regimen in the neoadjuvant treatment of operable ESCC currently lacks clinical data support.